Menu
  • Welcome
  • Resources
  • Webinars
  • News
  • Stats
  • Forums
  • Team
  • Contact
  • My Account
  • FR
  • Welcome
  • Resources
  • Webinars
  • News
  • Stats
  • Forums
  • Team
  • Contact
  • My Account
  • FR
home/Knowledge Base/Hematology

Lymphopenia as a Classification and Prediction Tool

171 views 0 04/01/2020 05/02/2020 Mathias Castonguay

  1. The LYM% (blood lymphocyte percentage) can be used as a reliable indicator to classify the infection as moderate, severe and critical independently of any other auxiliary indicators.
  2. TML (Time-LYM%-model) is a tool of classification and prognosis prediction. TML-1 is defined as the LYM% at day 10-12 after symptom onset and TML-2 is the LYM% at day 17-19 after symptom onset.
    • TML-1: LYM% > 20 % are classified moderate and can recover quickly, otherwise it’s classified as severe and may need medical attention.
    • TML-2: LYM% >20% are classified as in recovery, 5% < LYM% <20% are still in danger and need supervision, and LYM% <5% are critically ill with high mortality rate and need intensive care.

This figure was taken from https://www.nature.com/articles/s41392-020-0148-4#Fig1 and is published under an open access license. 

 

The TML was created with the analysis of 12 random death cases, 7 random cases severe infection and 11 random cases of moderate infection. The TML was afterward validated using 90 hospitalized patients. All the patients come from China.

Source : 

Tan L., Wang Q., Zhang D., et al. (March 27, 2020). Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. Nature. https://doi.org/10.1038/s41392-020-0148-4

Tags:prognosislymphopeniaTML

Was this helpful?

Yes  No
Related Articles
  • The Use of Corticosteroids in Adrenal Insufficiency
  • Thrombotic occlusive vasculopathy
  • Potential Effect of Complement Pathways in Thrombotic Microvascular Injury
  • Pediatric Multi-System Inflammatory Syndrome: A New Clinical Presentation in Children
  • Is Obesity a Risk Factor for Severity?
  • Acral Lesions: What We Know
Hematology
  • Lymphopenia as a Classification and Prediction Tool
  • Coagulopathy: What We Know So Far
  • Multiple Myeloma : Management Suggestions
  • A Case of Immune Thrombocytopenic Purpura (ITP)
  • G6PD-Deficiency: Risk of Infection and Treatment Related Adverse Events
  • Impacts on Patients with Acute Leukemia
View All 13  
Popular Articles
  • Acute Acro-Ischemic Lesions in Children
  • Insights About Reinfection and Immunization
  • What Is the Efficacy of Masks in Preventing Transmission?
  • Rationale of Old Antimalarial Drugs Against New Pandemic
  • Acral Lesions: What We Know
Specialties
  • Endocrinology
  • Anesthesiology
  • Cardiology
  • Dental Surgery
  • Dermatology
  • Emergency Medicine
  • ENT
  • Geriatrics and Palliative Care
  • Gastroenterology
  • Hematology
  • Infectious Diseases
  • Intensive Care
  • Neurology
  • OB-GYN
  • Oncology
  • Ophthalmology
  • Pediatrics
  • Pharmacology
  • Preventive Medicine
  • Protection of Healthcare Workers
  • Psychiatry
  • Public health
  • Other Internal Medicine Specialties
  • Radiology
  • Respirology
  • Stages of COVID-19 Infection
    • Presumption & Prevention
    • Screening & Diagnosis
    • Mild Infection
    • Moderate Infection
    • Severe Infection
    • Outcomes
  • Surgery
About How I Treat COVID-19

Our website is dedicated to helping healthcare professionals find accurate and up-to-date information about the best ways to manage and treat patients affected by the COVID-19 outbreak.

Navigation
  • Resources
  • News
  • Webinars
  • Forum
Useful Links
  • COVID-19 Protocols
  • Health Canada
  • WHO
  • CDC
Practice

  • Privacy Policy
  • Terms & Conditions
  • How I Treat Covid-19 © 2020 Made with ♥ by Mondien